J Liver Cancer Search

CLOSE


J Liver Cancer > Volume 22(2); 2022 > Article
Journal of Liver Cancer 2022;22(2):103-114.
DOI: https://doi.org/10.17998/jlc.2022.09.08    Published online September 22, 2022.
Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma
Eun-Ji Choi1  , Young-Joon Kim1,2 
1LepiDyne Co., Ltd., Seoul, Korea
2Department of Biochemistry, Yonsei University, Seoul, Korea
Correspondence:  Young-Joon Kim, Tel: +82-2-2123-2628, Fax: +82-2-6077-7631, 
Email: yjkim@yonsei.ac.kr
Received: August 3, 2022   • Revised: September 6, 2022   • Accepted: September 8, 2022
Abstract
Advances in our knowledge of the molecular characteristics of hepatocellular carcinoma (HCC) have enabled significant progress in the detection and therapeutic prediction of HCC. As a non-invasive alternative to tissue biopsy, liquid biopsy examines circulating cellular components such as exosomes, nucleic acids, and cell-free DNA found in body fluids (e.g., urine, saliva, ascites, and pleural effusions) and provides information about tumor characteristics. Technical advances in liquid biopsy have led to the increasing adoption of diagnostic and monitoring applications for HCC. This review summarizes the various analytes, ongoing clinical trials, and case studies of United States Food and Drug Administrationapproved in vitro diagnostic applications for liquid biopsy, and provides insight into its implementation in managing HCC.
Key Words: Hepatocellular carcinoma; Liquid biopsy; Cell-free nucleic acids; Early diagnosis; Therapeutic drug monitoring


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR AUTHORS AND REVIEWERS
Editorial Office
620 Yeoksam Heights Bldg.(FASTFIVE),151 Teheran-ro, Gangnam-gu, Seoul 06132, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2022 by The Korean Liver Cancer Association.

Developed in M2PI

Close layer
prev next